Q-omics provides the consensus-scored IL31RA profile across patient tissues and cancer cell-line models. IL31RA expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IL31RA is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, IL31RA RNA expression shows 15,178 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight UVM, HNSC, and ESCA as cancer lineages where IL31RA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL31RA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL31RA survival associations across molecular data types. IL31RA RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL31RA RNA expression–survival associations across cancer types. High IL31RA expression shows unfavorable associations in UVM, MESO, ACC and PAAD, but favorable associations in UCEC and SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IL31RA RNA expression.
This table summarizes IL31RA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for IL31RA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL31RA shows higher tumor expression in HNSC, LUAD, LUSC, KIRP, THCA and CHOL. The HNSC box plot shows higher IL31RA RNA expression in tumor versus normal tissue (log2 FC = +1.716, t-test p < 0.001).
This table shows molecular features associated with IL31RA in patient tissues and cancer cell lines. In patient samples, IL31RA shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, IL31RA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
